Alzheimer’s blood tests are used to measure proteins and biomarkers in the bloodstream that indicate whether someone has Alzheimer’s disease or is at risk of developing it. These tests can detect amyloid-beta, tau, and phosphorylated tau—molecular signatures of Alzheimer’s pathology—long before cognitive symptoms appear. A 68-year-old woman with a family history of Alzheimer’s and no memory problems might get a blood test as part of a research study and discover elevated phosphorylated tau (p-tau), revealing that her brain is already accumulating disease-related changes.
Unlike cognitive screening tests or imaging studies that require time and expense, blood tests offer a simple, scalable way to identify who has Alzheimer’s-related brain changes. They’re not yet standard in routine primary care for everyone, but they’re increasingly used in memory clinics, research settings, and by neurologists evaluating cognitive concerns. The tests help answer a fundamental question: Is someone’s cognitive decline or memory complaints caused by Alzheimer’s, or by something else entirely?.
Table of Contents
- How Blood Tests Detect Alzheimer’s Biomarkers in the Bloodstream
- The Specific Blood Tests Available Today and What They Measure
- Blood Tests Compared to Brain Imaging and Cognitive Screening
- How Blood Tests Support Early Detection and Intervention
- Important Limitations and Uncertainties of Alzheimer’s Blood Tests
- The Role of Blood Tests in Research and Clinical Trials
- When and How to Get an Alzheimer’s Blood Test
- Frequently Asked Questions
How Blood Tests Detect Alzheimer’s Biomarkers in the Bloodstream
Blood tests detect biomarkers—biological signals of disease—that leak from the brain into the bloodstream. When amyloid plaques and tau tangles accumulate in the Alzheimer’s brain, fragments and altered forms of these proteins enter the cerebrospinal fluid surrounding the brain and eventually appear in the blood. Detecting these markers through a simple blood draw is far more practical than a lumbar puncture (spinal tap), which was previously the only way to measure these proteins. The most commonly measured biomarkers are amyloid-beta 42 (a form associated with Alzheimer’s), total tau, and phosphorylated tau variants (p-tau181 and p-tau217).
Each marker tells a different part of the story. Amyloid-beta 42 tends to decrease in Alzheimer’s disease, phosphorylated tau increases, and total tau may rise as neurons are damaged. A person with memory complaints and elevated phosphorylated tau in their blood is much more likely to have Alzheimer’s pathology in their brain than someone with normal biomarker levels. The tests measure these proteins in incredibly small quantities—requiring sophisticated laboratory techniques—but that sensitivity is also their strength.
The Specific Blood Tests Available Today and What They Measure
Several blood tests have now received FDA approval or clinical validation for Alzheimer’s detection. The phospho-tau tests (p-tau181 and p-tau217) are among the most specific—they identify people whose brains are accumulating tau pathology, which is central to Alzheimer’s disease. Plasma phosphorylated tau tests show strong correlation with PET imaging of tau in the brain, meaning results often match what you’d see on expensive brain scans. A major limitation of these tests is that elevated biomarkers don’t diagnose Alzheimer’s disease itself—they only show that Alzheimer’s-related changes are happening in the brain.
Someone can have amyloid plaques and tau tangles without any cognitive symptoms (a state called preclinical Alzheimer’s), and some people with these changes never develop dementia in their lifetime. Additionally, not all memory loss is due to Alzheimer’s; similar cognitive decline can result from Lewy body disease, frontotemporal dementia, vascular changes, depression, or sleep disorders. A blood test showing abnormal biomarkers needs to be interpreted alongside cognitive testing, brain imaging if necessary, and medical history. The tests are also not yet universally covered by insurance, and access varies by region and research availability.
Blood Tests Compared to Brain Imaging and Cognitive Screening
Cognitive screening tests (like the Mini-Cog or Montreal Cognitive Assessment) measure how well someone can remember, think, and solve problems—they detect when thinking has actually changed. Brain imaging with PET or MRI shows the physical accumulation of plaques, tangles, and brain shrinkage. Blood tests reveal biomarkers at the molecular level, often years before cognitive decline or obvious brain changes appear on an MRI. The advantage of blood tests over imaging is availability, cost, and acceptability.
A PET scan can cost $3,000 to $5,000 and isn’t widely available; an MRI runs $800 to $2,000 and can trigger anxiety in people with claustrophobia. A blood test costs $200 to $500 and requires only a needle stick. However, blood tests are less detailed than imaging—a PET scan shows exactly where in the brain amyloid or tau is accumulating, while a blood test gives only a global measure of these proteins in circulation. For someone whose cognitive testing is normal but whose biomarkers are abnormal, brain imaging may be needed to clarify whether there truly is Alzheimer’s pathology present or whether the results are a false positive.
How Blood Tests Support Early Detection and Intervention
Blood tests enable detection of Alzheimer’s disease at the preclinical stage—before memory loss or cognitive decline occurs—which opens the window for preventive treatments. The FDA has approved or is fast-tracking disease-modifying drugs like lecanemab and donanemab that slow cognitive decline when given to people with mild cognitive impairment or mild dementia. The earlier someone starts these medications, the more cognitive decline they may prevent. A 64-year-old with normal cognition but abnormal biomarkers (revealed by blood test) can start a preventive drug now rather than waiting until memory problems are obvious, potentially extending their years of independent function.
In research settings, blood tests have become the standard biomarker tool for tracking how well new treatments are working. Instead of scanning someone’s brain with PET every few months (expensive and time-consuming), researchers can measure blood biomarkers to see whether medication is reducing amyloid or tau. However, biomarker improvement doesn’t always mean cognitive improvement—someone’s tau levels might drop while their memory still declines if other brain regions are damaged. This gap between biological changes and functional outcomes remains an open question in Alzheimer’s treatment research.
Important Limitations and Uncertainties of Alzheimer’s Blood Tests
A critical limitation is that abnormal blood biomarkers predict Alzheimer’s risk, not destiny. Many people with elevated amyloid and tau never develop cognitive symptoms in their lifetime, especially if they’re cognitively normal at the time of testing. Publishing results showing someone has preclinical Alzheimer’s can create anxiety and psychological harm—they may worry about a disease that may never functionally affect them. Insurance companies and employers could theoretically use biomarker results to deny coverage or opportunities, though legal protections against genetic discrimination have been discussed but not yet fully applied to blood-based biomarker testing.
Another limitation is that blood tests require standardized lab procedures, and results can vary between labs and testing companies. A person tested by one company might get a different interpretation than someone tested by another. The tests are also not appropriate for everyone—they’re most useful in the context of cognitive symptoms or significant family history, not as mass screening tools. A cognitively normal 55-year-old with no family history of dementia who gets an abnormal biomarker result faces an uncertain decision about how to respond, since the relationship between early biomarker changes and eventual symptoms is still being studied.
The Role of Blood Tests in Research and Clinical Trials
Alzheimer’s blood tests have transformed clinical research by making it faster and cheaper to enroll patients in drug trials and track treatment response. Previously, researchers relied on costly amyloid or tau PET scans and cognitive testing performed annually. Now they can use blood tests to screen potential participants, monitor who’s actually amyloid-positive (ensuring the trial includes people with the disease), and measure changes in biomarkers over time.
This shift has accelerated the pace of Alzheimer’s drug development and made trials accessible to participants in smaller cities and rural areas who don’t have access to specialized imaging centers. Blood tests have also enabled the identification of Alzheimer’s subtypes and atypical presentations. Some people have significant amyloid accumulation but minimal tau (amyloid-dominant), while others show the opposite pattern. These biomarker profiles may predict different trajectories and treatment responses, helping researchers understand why some people decline slowly and others rapidly.
When and How to Get an Alzheimer’s Blood Test
Blood tests for Alzheimer’s are currently not part of routine primary care screening, but they should be discussed with a doctor if you have cognitive concerns, a significant family history of dementia, or you’re participating in a research study. Memory clinics and neurologists have the most experience interpreting these tests and explaining what abnormal results mean.
A standard blood draw can be done at most hospitals, labs, or clinics that order the test, though not every lab offers all the tests—some specialize in phospho-tau, others in amyloid ratios. Before getting tested, it’s worth asking your doctor what the results will mean for your care. If your test is abnormal, will a neurologist recommend brain imaging? Will you be offered a preventive medication? Do you want to know your status if you have no symptoms, given the psychological weight of that knowledge? These conversations help ensure the test serves your actual health goals rather than generating anxiety or unnecessary follow-up.
Frequently Asked Questions
Can a blood test definitively diagnose Alzheimer’s disease?
No. Blood tests detect biomarkers associated with Alzheimer’s, but they don’t prove someone has the disease or will develop symptoms. Cognitive decline, medical history, and often brain imaging are needed for a diagnosis.
How accurate are Alzheimer’s blood tests?
For detecting amyloid and tau pathology in the brain, blood tests like phospho-tau217 show 90%+ correlation with PET imaging. However, accuracy for predicting who will develop cognitive decline is lower, around 70-85%.
Are these tests covered by insurance?
Coverage varies. Some insurance plans cover blood biomarker tests if ordered by a neurologist for cognitive complaints, but many do not yet. Research settings often provide free testing.
What should someone do if their blood test is abnormal but they have no memory problems?
Discuss results with a neurologist. Options may include repeat testing, brain imaging, baseline cognitive testing, or discussion of preventive medications and lifestyle modifications.
How often do blood tests need to be repeated?
That depends on your situation and doctor’s recommendations. If you’re starting a preventive medication, testing every 6-12 months might be useful to track treatment response.
Can blood tests rule out Alzheimer’s?
Normal biomarkers make Alzheimer’s disease less likely, but don’t completely rule it out. Other forms of dementia and conditions like depression can cause cognitive decline despite normal biomarkers.
